Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Arvinas, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies using its proprietary PROTAC technology to degrade disease-causing proteins. Targeting oncology and neurodegenerative diseases, its key products include vepdegestrant for breast cancer and ARV-102 for Parkinson's disease. With a robust pipeline addressing historically undruggable targets, Arvinas aims to transform treatment paradigms and improve patient outcomes through strategic collaborations and advanced drug development initiatives.
This description was generated via AI from an annual report. Updated about 1 year ago.